Similar GD2.CAR-T cells had already been successfully evaluated in clinical trials.5 Whatever the model system, the results were always the same and demonstrated a significant activity of ALK.CAR-T cells against high-ALK neuroblastoma and against low-ALK neuroblastoma, if combined with lorlatinib in the latter case (Fig. 1). The gene discussed is ALK; the disease is neuroblastoma.